# Combination Weekly Taxotere™ With Iressa™ /Placebo in Metastatic Breast Cancer

> **NCT00319618** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 66 (—)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Gefitinib
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00319618
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** —
- **Final completion:** 2006-06
- **Target enrollment:** 66 (—)
- **Last updated:** 2007-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00319618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00319618, "Combination Weekly Taxotere™ With Iressa™ /Placebo in Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00319618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*